Novartis1d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Novartis9d
Novartis named first-ever corporate pharmaceutical partner of the National Football League
The long-term, exclusive pharmaceutical category agreement is designed to turn fans' passion for the game into a commitment to better health Novartis sports partnership covers the NFL's marquee health ...
Novartis15d
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Shareholders approved 28 th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board ...
Novartis3d
Career Search
Explore opportunities with Novartis below.
Novartis5d
Novartis Indonesia
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Novartis2d
Career Search
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis13d
Career Search
Job Title Sort ascending Business Location Site Date Posted New Product Launch Lead Regular, Full time Innovative Medicines China Shanghai (Shanghai) Mar 17, 2025 Technical Producer Regular, Full time ...
Novartis8d
Career search
Job Title Sort ascending Business Location Site Date Posted （高级）区域市场经理 Regular, Full time Innovative Medicines China Hangzhou (Zhejiang Province) Mar 07, 2025 Analyst, Digital Regular, Full time ...